Роль тирозинкиназы Брутона в патогенезе хронической спонтанной крапивницы и перспективы применения новых лекарственных препаратов
- Авторы: Феденко Е.С.1, Елисютина О.Г.1,2, Ильина Н.И.1
-
Учреждения:
- Государственный научный центр «Институт иммунологии»
- Российский университет дружбы народов имени Патриса Лумумбы
- Выпуск: Том 21, № 2 (2024)
- Страницы: 265-282
- Раздел: Научные обзоры
- URL: https://journals.rcsi.science/raj/article/view/260061
- DOI: https://doi.org/10.36691/RJA16941
- ID: 260061
Цитировать
Аннотация
Хроническая спонтанная крапивница ― достаточно распространённое заболевание с непредсказуемым течением, обременяющими симптомами и значительным негативным влиянием на качество жизни пациентов. Несмотря на устоявшийся ступенчатый подход лечения антигистаминными препаратами в стандартных и повышенных дозировках и анти-IgE, у ряда пациентов сохраняется неудовлетворительный контроль симптомов крапивницы с необходимостью разработки препаратов, таргетно воздействующих на новые терапевтические мишени. Мастоциты (тучные клетки), базофилы и B-клетки ― ключевые элементы, задействованные в патогенезе крапивницы: регуляция процессов активации, дифференциации, пролиферации, секреции цитокинов и дегрануляции во всех трёх типах клеток осуществляется через сигнальную передачу с участием тирозинкиназы Брутона. Подавление её активности рассматривается в качестве новой терапевтической стратегии хронической спонтанной крапивницы.
В обзоре представлен современный взгляд на патогенез хронической спонтанной крапивницы, роль тирозинкиназы Брутона, историю медицинского применения ингибиторов тирозинкиназы Брутона, в том числе приведены клинические данные по применению новых ингибиторов тирозинкиназы Брутона у пациентов с хронической спонтанной крапивницей, не достигших достаточного контроля при лечении антигистаминными препаратами.
Полный текст
Открыть статью на сайте журналаОб авторах
Елена Сергеевна Феденко
Государственный научный центр «Институт иммунологии»
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-код: 5012-7242
д-р мед. наук, профессор
Россия, МоскваОльга Гурьевна Елисютина
Государственный научный центр «Институт иммунологии»; Российский университет дружбы народов имени Патриса Лумумбы
Автор, ответственный за переписку.
Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-код: 9567-1894
д-р мед. наук
Россия, Москва; МоскваНаталья Ивановна Ильина
Государственный научный центр «Институт иммунологии»
Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-код: 6715-5650
д-р мед. наук, профессор
Россия, МоскваСписок литературы
- Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73, N 7. P. 1393–1414. EDN: YCCVNB doi: 10.1111/all.13397
- Gonçalo M., Gimenéz-Arnau A., Al-Ahmad M., et al. The global burden of chronic urticaria for the patient and society // Br J Dermatol. 2021. Vol. 184, N 2. P. 226–236. EDN: YLXKFV doi: 10.1111/bjd.19561
- Curto-Barredo L., Archilla L.R., Vives G.R., et al. Clinical features of chronic spontaneous urticarial that predict disease prognosis and refractoriness to standard treatment // Acta Derm Venereol. 2018. Vol. 98, N 7. P. 641–647. EDN: YJEFVJ doi: 10.2340/00015555-2941
- Melé-Ninot G., Serra-Baldrich E., Curto-Barredo L., et al. Definition of recurrent chronic spontaneous urticaria // Acta Derm Venereol. 2020. Vol. 100, N 16. P. adv00267. doi: 10.2340/00015555-3633
- Maurer M., Abuzakouk M., Bérard F., et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU // Allergy. 2017. Vol. 72, N 12. P. 2005–2016. doi: 10.1111/all.13209
- Попова К.Ю., Заборова В.А., Куршев В.В., и др. Клинические предикторы резистентности к антигистаминным препаратам у пациентов с хронической спонтанной крапивницей // Российский аллергологический журнал. 2023. Т. 20, № 4. C. 402–414. EDN: DIMFTH doi: 10.36691/RJA7951
- Guillén-Aguinaga S., Jáuregui Presa I., Aguinaga-Ontoso E., et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis // Br J Dermatol. 2016. Vol. 175, N 6. P. 1153–1165. doi: 10.1111/bjd.14768
- Maurer M., Costa C., Gimenez Arnau A., et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study // Clin Exp Allergy. 2020. Vol. 50, N 10. P. 1166–1175. EDN: ZTUTPO doi: 10.1111/cea.13716
- Kaplan A., Lebwohl M., Gimenez-Arnau A.M., et al. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances // Allergy. 2023. Vol. 78, N 2. P. 389–401. EDN: LFRXKZ doi: 10.1111/all.15603
- Konstantinou G.N., Riedl M.A., Valent P., et al. Urticaria and angioedema: Understanding complex pathomechanisms to facilitate patient communication, disease management, and future treatment // J Allergy Clin Immunol Pract. 2023. Vol. 11, N 1. P. 94–106. EDN: YUKJKQ doi: 10.1016/j.jaip.2022.11.006
- Kolkhir P., Gimenez-Arnau A.M., Kulthanan K., et al. Urticaria // Nat Rev Dis Primers. 2022. Vol. 8, N 1. P. 61. doi: 10.1038/s41572-022-00389-z
- Alvarado D., Maurer M., Gedrich R., et al. The anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study // Allergy. 2022. Vol. 77, N 8. P. 2393–2403. EDN: KVXABO doi: 10.1111/all.15262
- Kolkhir P., Elieh-Ali-Komi D., Metz M., et al. Understanding human mast cells: Lesson from therapies for allergic and non-allergic diseases // Nat Rev Immunol. 2022. Vol. 22, N 5. P. 294–308. EDN: OETTCH doi: 10.1038/s41577-021-00622-y
- Asero R., Marzano A.V., Ferrucci S., et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria // Clin Exp Immunol. 2020. Vol. 200, N 3. P. 242–249. EDN: JEUSWQ doi: 10.1111/cei.13428
- Xiang Y.K., Kolkhir P., Scheffel J., et al. Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa // J Allergy Clin Immunol Pract. 2023. Vol. 11, N 8. P. 2417–2425.e1. EDN: XNPDRK doi: 10.1016/j.jaip.2023.02.006
- Schmetzer O., Lakin E., Topal F.A., et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria // J Allergy Clin Immunol. 2018. Vol. 142, N 3. P. 876–882. EDN: YFVOAX doi: 10.1016/j.jaci.2017.10.035
- Cugno M., Asero R., Ferrucci S., et al. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria // Allergy. 2018. Vol. 73, N 12. P. 2408–2411. EDN: VHAZYR doi: 10.1111/all.13587
- Su H., Kolkhir P., Scheffel J., et al. One in five patients with chronic spontaneous urticaria has IgE to tissue transglutaminase 2 // Allergy. 2023. Vol. 78, N 9. P. 2537–2539. EDN: JGBWHQ doi: 10.1111/all.15734
- Altrichter S., Peter H.J., Pisarevskaja D., et al. IgE mediated autoallergy against thyroid peroxidase: A novel pathomechanism of chronic spontaneous urticaria? // PLoS One. 2011. Vol. 6, N 4. P. e14794. doi: 10.1371/journal.pone.0014794
- Hide M., Francis D.M., Grattan C.E., et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria // N Engl J Med. 1993. Vol. 328, N 22. P. 1599–1604. doi: 10.1056/NEJM199306033282204
- Niimi N., Francis D.M., Kermani F., et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria // J Invest Dermatol. 1996. Vol. 106, N 5. P. 1001–1006. doi: 10.1111/1523-1747.ep12338544
- Altrichter S., Zampeli V., Ellrich A., et al. IgM and IgA in addition to IgG autoantibodies against FcεRIα are frequent and associated with disease markers of chronic spontaneous urticaria // Allergy. 2020. Vol. 75, N 12. P. 3208–3215. EDN: KIJGPP doi: 10.1111/all.14412
- Jang J.H., Moon J., Yang E.M., et al. Detection of serum IgG autoantibodies to FcεRIα by ELISA in patients with chronic spontaneous urticaria // PLoS One. 2022. Vol. 17, N 8. P. e0273415. EDN: LCLZXT doi: 10.1371/journal.pone.0273415
- Zhou B., Li J., Liu R., et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria // Front Immunol. 2022. N 13. P. 879754. EDN: VARNXK doi: 10.3389/fimmu.2022.879754
- Борзова Е.Ю. Новые аспекты патогенеза хронической крапивницы // Российский аллергологический журнал. 2012. Т. 9, № 5. C. 3–9. EDN: PEIQIN doi: 10.36691/RJA671
- Gimėnez-Arnau A.M., de Montojoye L., Asero R., et al. The pathogenesis of chronic spontaneous urticaria: The role of infiltrating cells // J Allergy Clin Immunol Pract. 2021. Vol. 9, N 6. P. 2195–2208. EDN: KYPUGA doi: 10.1016/j.jaip.2021.03.033
- Kishimoto I., Ma N., Takimoto-Ito R., et al. Decreased peripheral basophil counts in urticaria and mouse model of oxazolone-induced hypersensitivity, the latter suggesting basopenia reflectingmigration to skin // Front Immunol. 2022. N 13. P. 1014924. EDN: TAYEIZ doi: 10.3389/fimmu.2022.1014924
- Grattan C.E., Dawn G., Gibbs S., Francis D.M. Blood basophil numbers in chronic ordinary urticaria and healthy controls: Diurnal variation, influence of loratadine and prednisolone and relationship to disease activity // Clin Exp Allergy. 2003. Vol. 33, N 3. P. 337–341. EDN: BEUGQH doi: 10.1046/j.1365-2222.2003.01589.x
- Oliver E.T., Sterba P.M., Saini S.S. Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria // Allergy. 2015. Vol. 70, N 5. P. 601–603. doi: 10.1111/all.12578
- Kern F., Lichtenstein L.M. Defective histamine release in chronic urticaria // J Clin Invest. 1976. Vol. 57, N 5. P. 1369–1377. doi: 10.1172/JCI108405
- Oda Y., Fukunaga A., Washio K., et al. Low responsiveness of basophils via FcεRI reflects disease activity in chronic spontaneous urticaria // J Allergy Clin Immunol Pract. 2019. Vol. 7, N 8. P. 2835–2844. EDN: YNSKBK doi: 10.1016/j.jaip.2019.05.020
- Lourenco F.D., Azor M.H., Santos J.C., et al. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus // Br J Dermatol. 2008. Vol. 158, N 5. P. 979–986. doi: 10.1111/j.1365-2133.2008.08499.x
- Zuberbier T., Abdul Latiff A.H., Abuzakouk M., et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria // Allergy. 2022. Vol. 77, N 3. P. 734–766. EDN: NEWKMD doi: 10.1111/all.15090
- Steinweg S.A., Gaspari A.A. Rituximab for the treatment of recalcitrant chronic autoimmune urticaria // J Drugs Dermatol. 2015. Vol. 14, N 12. P. 1387.
- Chakravarty S.D., Yee A.F., Paget S.A. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies // J Allergy Clin Immunol. 2011. Vol. 128, N 6. P. 1354–1355. doi: 10.1016/j.jaci.2011.08.023
- Combalia A., Losno R.A., Prieto-González S., Mascaró J.M. Rituximab in refractory chronic spontaneous urticaria: An encouraging therapeutic approach // Skin Pharmacol Physiol. 2018. Vol. 31, N 4. P. 184–188. doi: 10.1159/000487402
- Mendes-Bastos P., Brasileiro A., Kolkhir P., et al. Bruton’s tyrosine kinase inhibition: An emerging therapeutic strategy in immune-mediated dermatological conditions // Allergy. 2022. Vol. 77, N 8. P. 2355–2366. doi: 10.1111/all.15261
- Neys S.F., Hendriks R.W., Corneth O.B. Targeting Bruton’s tyrosine kinase in inflammatory and autoimmune pathologies // Front Cell Dev Biol. 2021. N 9. P. 668131. doi: 10.3389/fcell.2021.668131
- Rip J., van der Ploeg E.K., Hendriks R.W., Corneth O.B. The role of Bruton’s tyrosine kinase in immune cell signaling and systemic autoimmunity // Crit Rev Immunol. 2018. Vol. 38, N 1. P. 17–62. doi: 10.1615/CritRevImmunol.2018025184
- Smith C.I., Baskin B., Humire-Greiff P., et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells // J Immunol. 1994. Vol. 152, N 2. P. 557–565.
- Weber A.N., Bittner Z., Liu X., et al. Bruton’s tyrosine kinase: An emerging key player in innate immunity // Front Immunol. 2017. N 8. P. 1454. doi: 10.3389/fimmu.2017.01454
- Carnero Contentti E., Correale J. Current perspectives: Evidence to date on BTK inhibitors in the management of multiple sclerosis // Drug Des Devel Ther. 2022. N 16. P. 3473–3490. doi: 10.2147/DDDT.S348129
- Zhu S., Gokhale S., Jung J., et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets-beyond B lymphocytes // Front Cell Dev Biol. 2021. N 9. P. 727531. EDN: MQEUZR doi: 10.3389/fcell.2021.727531
- Alu A., Lei H., Han X., et al. BTK inhibitors in the treatment of haematological malignancies and inflammatory diseases: Mechanisms and clinical studies // J Hematol Oncol. 2022. Vol. 15, N 1. P. 138. EDN: JLZNYD doi: 10.1186/s13045-022-01353-w
- Wahl M.I., Fluckiger A.C., Kato R.M., et al. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton’s tyrosine kinase via alternative receptors // Proc Natl Acad Sci USA. 1997. Vol. 94, N 21. P. 11526–11533. doi: 10.1073/pnas.94.21.11526
- Turner H., Kinet J.P. Signalling through the high-affinity IgE receptor Fc epsilon RI // Nature. 1999. Vol. 402, N 6760, Suppl. P. B24–В30. doi: 10.1038/35037021
- Bradshaw J.M. The Src, Syk, and Tec family kinases: Distinct types of molecular switches // Cell Signal. 2010. Vol. 22, N 8. P. 1175–1184. doi: 10.1016/j.cellsig.2010.03.001
- Rawlings D.J., Scharenberg A.M., Park H., et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases // Science. 1996. Vol. 271, N 5250. P. 822–825. doi: 10.1126/science.271.5250.822
- Rozkiewicz D., Hermanowicz J.M., Kwiatkowska I., et al. Bruton’s tyrosine kinase inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials // Molecules. 2023. Vol. 28, N 5. P. 2400. doi: 10.3390/molecules28052400
- Singh P.S., Dammeijer F., Hendriks R.W. Role of Bruton’s tyrosine kinase in B cells and malignancies // Mol Cancer. 2018. Vol. 17, N 1. P. 57. doi: 10.1186/s12943-018-0779-z
- Satterthwaite A.B., Li Z., Witte O.N. Btk function in B cell development and response // Semin Immunol. 1998. Vol. 10, N 4. P. 309–316. doi: 10.1006/smim.1998.0123
- Khan W.N., Sideras P., Rosen F.S., Alt F.W. The role of Bruton’s tyrosine kinase in B-cell development and function in mice and man // Ann NY Acad Sci. 1995. N 764. P. 27–38. doi: 10.1111/j.1749-6632.1995.tb55802.x
- McDonald C., Xanthopoulos C., Kostareli E. The role of Bruton’s tyrosine kinase in the immune system and disease // Immunology. 2021. Vol. 164, N 4. P. 722–736. doi: 10.1111/imm.13416
- Rip J., de Bruijn M.J., Appelman M.K., et al. Toll-like receptor signaling drives Btk-mediated autoimmune disease // Front Immunol. 2019. N 10. P. 95. doi: 10.3389/fimmu.2019.00095
- Kong W., Deng W., Sun Y., et al. Increased expression of Bruton’s tyrosine kinase in peripheral blood is associated with lupus nephritis // Clin Rheumatol. 2018. Vol. 37, N 1. P. 43–49. doi: 10.1007/s10067-017-3717-3
- Corneth O.B., Verstappen G.M., Paulissen S.M., et al. Enhanced Bruton’s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease // Arthritis Rheumatol. 2017. Vol. 69, N 6. P. 1313–1324. doi: 10.1002/art.40059
- Robak E., Robak T. Bruton’s kinase inhibitors for the treatment of immunological diseases: Current status and perspectives // J Clin Med. 2022. Vol. 11, N 10. P. 2807. doi: 10.3390/jcm11102807
- Hantschel O., Rix U., Schmidt U., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib // Proc Natl Acad Sci USA. 2007. Vol. 104, N 33. P. 13283–13288. EDN: MMRISH doi: 10.1073/pnas.0702654104
- Kneidinger M., Schmidt U., Rix U., et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils // Blood. 2008. Vol. 111, N 6. P. 3097–3107. doi: 10.1182/blood-2007-08-104372
- Kaptein A., de Bruin G., Emmelot-van Hoek M., et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies // Blood. 2018. Vol. 132, Suppl. 1. P. 1871. doi: 10.1182/blood-2018-99-109973
- Regan J.A., Cao Y., Dispenza M.C., et al. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity // J Allergy Clin Immunol. 2017. Vol. 140, N 3. P. 875–879. doi: 10.1016/j.jaci.2017.03.013
- Dispenza M.C., Krier-Burris R.A., Chhiba K.D., et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis // J Clin Invest. 2020. Vol. 130, N 9. P. 4759–4770. doi: 10.1172/JCI138448
- Ellmeier W., Abramova A., Schebesta A. Tec family kinases: Regulation of FcεRI-mediated mast-cell activation // FEBS J. 2011. Vol. 278, N 12. P. 1990–2000. doi: 10.1111/j.1742-4658.2011.08073.x
- Suresh R., Dunnam C., Vaidya D., et al. The BTK inhibitor acalabrutinib reduces or eliminates clinical reactivity during oral challenge to peanut in allergic adults // J Allergy Clin Immunol. 2023. Vol. 151, N 2. P. AB221. doi: 10.1016/j.jaci.2022.12.688
- McGlashan D.J., Honigberg L.A., Smith A., et al. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton’s tyrosine kinase, Btk, inhibitor // Int Immunopharmacol. 2011. Vol. 11, N 4. P. 475–479. doi: 10.1016/j.intimp.2010.12.018
- Smiljkovic D., Blatt K., Stefanzl G., et al. BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils // Allergy. 2017. Vol. 72, N 11. P. 1666–1676. doi: 10.1111/all.13166
- Angst D., Gessier F., Janser P., et al. Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase // J Med Chem. 2020. Vol. 63, N 10. P. 5102–5118. doi: 10.1021/acs.jmedchem.9b01916
- Pulz R., Angst D., Eichlisberger D., Cenni B. Remibrutinib, a novel Bruton’s tyrosine kinase inhibitor, exhibits improved target selectivity and potency in vitro. EPO0896. Poster presented at: 38th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, October 26–28, 2022; Amsterdam, Netherlands, 2022.
- Mato A.R., Shah N.N., Jurczak W., et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study // Lancet. 2021. Vol. 397, N 10277. P. 892–901. doi: 10.1016/S0140-6736(21)00224-5
- Bender A.T., Gardberg A., Pereira A., et al. Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signalling // Mol Pharmacol. 2017. Vol. 91, N 3. P. 208–219. doi: 10.1124/mol.116.107037
- Crawford J.J., Johnson A.R., Misner D.L., et al. Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development // J Med Chem. 2018. Vol. 61, N 6. P. 2227–2245. doi: 10.1021/acs.jmedchem.7b01712
- Langrish C.L., Bradshaw J.M., Francesco M.R., et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease // J Immunol. 2021. Vol. 206, N 7. P. 1454–1468. doi: 10.4049/jimmunol.2001130
- Kaul M., End P., Cabanski M., et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial // Clin Transl Sci. 2021. Vol. 14, N 5. P. 1756–1768. doi: 10.1111/cts.13005
- Herman A.E., Chinn L.W., Kotwal S.G., et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton’s tyrosine kinase inhibitor // Clin Pharmacol Ther. 2018. Vol. 103, N 6. P. 1020–1028. doi: 10.1002/cpt.1056
- Metz M., Sussman G., Gagnon R., et al. Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: A randomized phase II trial // Nat Med. 2021. Vol. 27, N 11. P. 1961–1969. doi: 10.1038/s41591-021-01537-w
- Gimeno R., Ribas-Llauradó C., Pesque D., et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticarial patients independently of FcεR1 expression level and omalizumab clinical response // Clin Transl Allergy. 2023. Vol. 13, N 3. P. e12227. EDN: NRBQGZ doi: 10.1002/clt2.12227
- Ucpinar S., Smith P.F., Long L., et al. Rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants // Clin Transl Sci. 2023. Vol. 16, N 7. P. 1210–1219. doi: 10.1111/cts.13524
- Maurer M., Berger W., Gimėnez-Arnau A., et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria // J Allergy Clin Immunol. 2022. Vol. 150, N 6. P. 1498–1506. doi: 10.1016/j.jaci.2022.08.027
- Jain V., Giménez-Arnau A., Hayama K., et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks // J Allergy Clin Immunol. 2024. Vol. 153, N 2. P. 479–486.e4. doi: 10.1016/j.jaci.2023.10.007
- Carr W., Sitz K., Jain V., et al. Remibrutinib improves chronic spontaneous urticaria in patients irrespective of CU-index: Results from phase 2b study // Ann Allergy Asthma Immunol. 2022. Vol. 129, Suppl. 5. P. S11. EDN: LSUIDJ doi: 10.1016/j.anai.2022.08.537
- Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens // N Engl J Med. 2007. Vol. 357, N 19. P. 1903–1915. doi: 10.1056/NEJMoa066092
- Katewa A., Wang Y., Hackney J.A., et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNa-driven lupus nephritis // JCI Insight. 2017. Vol. 2, N 7. P. e90111. doi: 10.1172/jci.insight.90111
- Cohen S., Tuckwell K., Katsumoto T.R., et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: A randomized, double-blind, phase II trial (ANDES study) // Arthritis Rheumatol. 2020. Vol. 72, N 9. P. 1435–1446. EDN: XSWFJF doi: 10.1002/art.41275
- Isenberg D., Furie R., Jones N.S., et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double-blind, placebo-controlled trial // Arthritis Rheumatol. 2021. Vol. 73, N 10. P. 1835–1846. doi: 10.1002/art.41811
- Bernstein J.A., Maurer M., Saini S.S. BTK signalling: A crucial link in the pathophysiology of chronic spontaneous urticaria // J Allergy Clin Immunol. 2024. Vol. 153, N 5. P. 1229–1240. EDN: HFXINM doi: 10.1016/j.jaci.2023.12.008
- Saini S., Giménez-Arnau A., Hide M., et al. Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1/-2 studies // Ann Allergy, Asthma Immunol. 2023. Vol. 131, N 5. P. S230. doi: 10.1016/j.anai.2023.10.019
- Mlynek A., Zalewska-Janowska A., Martus P., et al. How to assess disease activity in patients with chronic urticaria? // Allergy. 2008. Vol. 63, N 6. P. 777–780. doi: 10.1111/j.1398-9995.2008.01726.x
- Hawro T., Ohanyan T., Schoepke N., et al. Comparison and interpretability of the available urticaria activity scores // Allergy. 2017. Vol. 73, N 1. P. 251–255. doi: 10.1111/all.13271
- Maas A., Hendriks R.W. Role of Bruton’s tyrosine kinase in B cell development // Dev Immunol. 2001. Vol. 8, N 3-4. P. 171–181. doi: 10.1155/2001/28962
- Nyhoff L.E., Clark E.S., Barron B.L., et al. Bruton’s tyrosine kinase is not essential for B cell survival beyond early developmental stages // J Immunol. 2018. Vol. 200, N 7. P. 2352–2361. doi: 10.4049/jimmunol.1701489
- Crofford L.J., Nyhoff L.E., Sheehan J.H., Kendall P.L. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy // Expert Rev Clin Immunol. 2016. Vol. 12, N 7. P. 763–773. doi: 10.1586/1744666X.2016.1152888
- Nyhoff L.E., Griffith A.S., Clark E.S., et al. Btk supports autoreactive B cell development and protects against apoptosis but is expendable for antigen presentation // J Immunol. 2021. Vol. 207, N 12. P. 2922–2932. doi: 10.4049/jimmunol.2000558
- Torke S., Pretzsch R., Häusler D., et al. Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease // Acta Neuropathol. 2020. Vol. 140, N 4. P. 535–548. doi: 10.1007/s00401-020-02204-z